Iris Rajman MD, PhD has been apponted as a new board member of Center for Translational Research (CTR).
Iris is a pharmaceutical industry executive with extensive senior leadership experience across global pharma companies. She brings deep expertise in translational medicine and portfolio governance, and has chaired several high-impact committees while overseeing more than a hundred regulatory registrations.
Her international experience, strategic insight, and strong industry network—combined with a proven track record of scaling organizations—will be invaluable as CTR continues the growth journey and expanding the international footprint.
At a time when the demand for high-quality R&D support is rapidly increasing, Iris expertise will help guide the strategic direction, support sustainable growth, and further strengthen how CTR will deliver value to both current and future customers.